ALEXANDRIA, Va., Feb. 17 -- United States Patent no. 12,552,758, issued on Feb. 17, was assigned to NeoPhore Ltd. (Altrincham, Great Britain).
"Inhibitors of MLH1 and/or PMS2 for cancer treatment" was invented by Julian Blagg (London), Jon Roffey (London), Martin Drysdale (London), Paul Winship (Saffron Walden, Great Britain) and David Clark (Saffron Walden, Great Britain).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to compounds of Formula (I) that target the MLH1 and/or PMS2 proteins that are components of the DNA Mismatch Repair (MMR) process: wherein R1, R2, R3, R4, R6 and R10 are each as defined herein. The present invention also relates to processes for the preparation of...